We would love to hear your thoughts about our site and services, please take our survey here.
HBD ref SRA737, I think the partner could possibly be Boehringer Ingelheim US subsidiary, technically this is a private US based company, ultimately owned by the parent in Germany. Boehringer Ingelheim Inc will have issued shares (private) and could therefore offer them as part of the deal.
Boehringer Ingelheim Collaborate extensively with Cancer Research Technology (trading as Cancer Research Horizons).
Full Disclosure of interactions with industry:
Sometimes, through Cancer Research Technology Limited, Cancer Research UK will receive shares rather than financial payments when research partnerships are created. Cancer Research UK does not usually apply a market value to such shareholdings but some information concerning these shareholdings can be found in Cancer Research Technology Limited’s statutory accounts filed at Companies House.
Boehringer are significantly involved in combo trials of xentuzumab with other drugs.
https://pubmed.ncbi.nlm.nih.gov/37308971/
Researchers based at the University of Oxford have discovered a way to boost the effectiveness of a new type of drug, called xentuzumab, which is currently being tested for breast cancer.
They found that xentuzumab was most effective when combined with drugs MK-8776 and SRA737, which block a protein called CHK1, and AZD1775 that blocks WEE1 protein.
https://breastcancernow.org/about-us/research-news/researchers-discover-way-boost-effectiveness-new-breast-cancer-drug/
“I am 83 years old I live in Spain I have lots of friends here and live in a nice house which is paid for. The place I live is called Torrevieja Costa blanks. And I am very happy.”
Was that a cut and paste from a dating website 😂😂
Nicely, I’ve never predicted a price. And if you believed anyone predicting £55 a share I think you need to stick to trading Pokémon cards in the playground. You would be far better off if you lost the bitterness. Ps making statements about what traders preferences are, thereby eluding that you are knowledgeable in the art of investing is embarrassing, particularly when you constantly bleat about having your pants down at £4.70.
Potty time for you.
Hi Brighty, I agree. However that only applies if SDC1801 is a better therapeutic, otherwise the NHS, it’s equivalents and health insurance providers will be inclined to prescribe the generic off patent drugs which are always significantly cheaper.